CWBR - CohBar, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.7000
-0.0900 (-3.23%)
At close: 04:00PM EDT
2.6900 -0.01 (-0.37%)
After hours: 07:57PM EDT
Stock chart is not supported by your current browser
Previous Close2.7900
Open3.0200
Bid0.0000 x 800
Ask0.0000 x 900
Day's Range2.6200 - 2.9500
52 Week Range1.4300 - 7.5000
Volume281,942
Avg. Volume866,229
Market Cap7.849M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.8500
Earnings DateAug 14, 2023 - Aug 18, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

    Combined company will operate under the name “TuHURA Biosciences, Inc.” and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and we

  • GlobeNewswire

    CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

    Conference call and webcast today at 5:00 p.m. ET, November 8, 2022MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. “I’m pleased

  • GlobeNewswire

    CohBar to Announce 2022 Third Quarter Financial Results and Provide Business Update on November 8, 2022

    Company to host conference call and webcast at 5:00 p.m. ETMENLO PARK, Calif., Oct. 26, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 third quarter financial results after the market closes on Tuesday, November 8, 2022. Managem

  • Zacks

    Cohbar Inc. (CWBR) Upgraded to Strong Buy: What Does It Mean for the Stock?

    Cohbar Inc. (CWBR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

  • GlobeNewswire

    CohBar Announces Reverse Stock Split

    MENLO PARK, Calif., Sept. 22, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced that its Board of Directors (the “Board”) has approved a 1-for-30 reverse stock split of the company’s common stock. The reverse stock split will become effective at 12:01am ET on September

  • GlobeNewswire

    CohBar to Present at H.C. Wainwright 24th Annual Global Investment Conference

    MENLO PARK, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company exploiting the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12 - 14, 2022. H.C.

  • GlobeNewswire

    CohBar Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

    IND for CB5138-3 on track for second half of 2023 Conference call and webcast today at 5:00 p.m. ET, August 15, 2022 MENLO PARK, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the second quarter ended June 30, 2022 and highli

  • GlobeNewswire

    CohBar to Announce 2022 Second Quarter Financial Results and Provide Business Update on August 15, 2022

    Company to host conference call and webcast at 5:00 p.m. ETMENLO PARK, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that the company will release its 2022 second quarter financial results after the market closes on Monday, August 15, 2022. Manageme

  • GlobeNewswire

    CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

    MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company’s Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both establ

  • Simply Wall St.

    We're Keeping An Eye On CohBar's (NASDAQ:CWBR) Cash Burn Rate

    We can readily understand why investors are attracted to unprofitable companies. For example, although...

  • GlobeNewswire

    CohBar to Participate at Upcoming Conferences in June 2022

    MENLO PARK, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, announced today that its Chief Executive Officer, Dr. Joseph Sarret, will participate at two upcoming conferences. BIO International Convention – June 13-16, 2022 June 14th at 5:00 pm PT, San Diego, CA The p